欧盟EMA药品数据库(European Medicines Agency Authorisation of Medicines DataBase)
商品名称Celldemic
适用类别Human
治疗领域Influenza, Human
通用名/非专利名称zoonotic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted, prepared in cell cultures)
活性成分Influenza virus A/turkey/Turkey/1/2005 (H5N1) NIBRG-23 strain, HA surface antigen
产品号EMEA/H/C/006052
患者安全信息No
许可状态Authorised
ATC编码J07BB02
是否额外监管Yes
是否仿制药或hybrid药物No
是否生物类似药No
是否附条件批准No
是否特殊情形No
是否加速审评No
是否罕用药No
上市许可日期2024/04/19
上市许可开发者/申请人/持有人Seqirus Netherlands B.V.
人用药物治疗学分组Vaccines
兽用药物治疗学分组
审评意见日期2024/02/22
欧盟委员会决定日期2024/11/14
修订号1
治疗适应症Celldemic is indicated for active immunisation against H5N1 subtype of Influenza A virus in adults and infants from 6 months of age and above. Celldemic should be used in accordance with official recommendations.
适用物种
兽用药物ATC编码
首次发布日期2024/02/23
最后更新日期2025/01/29
产品说明书https://www.ema.europa.eu/en/documents/product-information/celldemic-epar-product-information_en.pdf
公共评估报告https://www.ema.europa.eu/en/medicines/human/EPAR/celldemic
©2006-2025 DrugFuture->European Medicines Agency Authorisation of Medicines DataBase